
    
      Qualifying subjects will have a diagnosis of Neurofibromatosis 1 and have disfiguring
      cutaneous lesions that can be measured by photography. The subjects will have photographs of
      the target lesions,biopsies of the lesions,and safety blood laboratory tests at 3 time points
      (baseline, 3 months and 6 months which is end of treatment). Everolimus will be taken orally
      for 6 months. Subjects will visit the clinic monthly for an exam and adverse event
      evaluation. Laboratory testing will be done at these visits if determined necessary by the
      PI.
    
  